Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

Journal of Hepatology

Volumn 66, Issue 1, 2017, Pages 236-237

  Zavaglia, Claudio ^a   Okolicsanyi, Stefano ^b   Cesarini, Lucia ^a   Mazzarelli, Chiara ^a   Pontecorvi, Valerio ^b   Ciaccio, Antonio ^b   Strazzabosco, Mario ^b   Belli, Luca Saverio ^a,b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA;

AGED; ANTIVIRAL THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CHILD PUGH SCORE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; VIROLOGY; LIVER TUMOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 84995812392     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.016     Document Type: Letter

References (8)

1. [1] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
2. [2] Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 65 (2016), 727–733.
3. [3] Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol 65 (2016), 856–858.
4. [4] Yang, J.D., Aqel, B.A., Pungpapong, S., Gores, G.J., Roberts, L.R., Leise, M.D., Direct acting antiviral therapy and tumor recurrence after liver transplant for hepatitis C-associated hepatocellular carcinoma. J Hepatol 65 (2016), 859–860.
5. [5] Pol, S., Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma. J Hepatol 65 (2016), 734–740.
6. [6] Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 65 (2016), 861–862.
7. [7] Torres, H.A., Vauthey, J.-N., Economides, M.P., Mahale, P., Kaseb, A., Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol 65 (2016), 862–864.
8. [8] Nault, J.-C., Colombo, M., Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol 65 (2016), 663–665.